Boston Partners
EBS icon

Boston Partners’s Emergent Biosolutions EBS Stock Holding History

Boston Partners’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,527
Closed -$327K – 693
2021
Q3 		$327K Sell
6,527
-3,766
-37% -$228K ﹤0.01% 632
2021
Q2 		$648K Buy
+10,293
New +$661K ﹤0.01% 599

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $128B AUM 35.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boston Partners's EBS Position: Q4 2021 in Review

Boston Partners sold out of Emergent Biosolutions (EBS) in Q4 2021, closing a stake of 6,527 shares — an estimated $327K sold.

Boston Partners first reported a position in EBS in Q2 2021 and held it in 2 quarters. The position peaked at $648K in Q2 2021. 253 funds tracked by Wall St. Rank hold EBS as of Q4 2021.

  • Boston Partners reported no remaining Emergent Biosolutions position as of Q4 2021 after selling out during the quarter.
  • Boston Partners sold 6,527 Emergent Biosolutions shares in Q4 2021, an estimated $327K.
  • Boston Partners first reported a position in Emergent Biosolutions in Q2 2021 and held it in 2 quarters.
  • Boston Partners's Emergent Biosolutions position peaked at $648K in Q2 2021.
  • 253 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q4 2021.

Based on Boston Partners's 13F filing for Q4 2021, filed 4 Feb 2022.